$8 Billion Bombshell: Curium Buys Lantheus in Biggest Radiopharma Deal of 2026
On August 3, 2026, the radiopharmaceutical industry witnessed one of its biggest deals of the year. Curium , a leading global radiopharmaceutical company backed by private equity firm CapVest, announced a definitive agreement to acquire Lantheus Holdings (NASDAQ: LNTH) in a deal valued at up to $8 billion . This is not just another acquisition — it is a strategic move that could reshape the nuclear medicine and cancer diagnostics landscape. IBA Molecular and Mallinckrodt Nuclear Medicine LLC to create a new, world-class radiopharmaceutical company: Curium - Curium Pharma Deal Structure at a Glance Particulars Details Buyer Curium US Holdings Target Lantheus Holdings Upfront Cash $102.50 per share Contingent Value Rights (CVR) Up to $12.00 per share Total Potential Value Up to $114.50 per share Total Deal Size Up to $8 billion Expected Closing First half of 2027 Lantheus shareholders will receive $102.50 in cash at closing, plus non-tr...